CHEST
Selected ReportsPregnancy and Primary Pulmonary Hypertension: Successful Outcome With Epoprostenol Therapy
Section snippets
Case Report
A 35-year-old, gravida (G2,P0) patient with a history of hypothyroidism presented at 26 weeks' gestation with progressiveexertional dyspnea and fatigue of several weeks duration. She alsoreported several recent syncopal episodes. Her first pregnancy wasuncomplicated, and she denied prior cardiopulmonary disease, illicitdrug use, or ingestion of anorexigens. On physical examination, hervital signs were as follows: BP, 90/60 mm Hg; heart rate, 105beats/min; respiratory rate, 20 breaths/min; and
Discussion
An early case series reported a 50% mortality rateassociated with pregnancy and PPH.1 A more recent accountnoted a 30% mortality rate2 and partly attributed thedecline in the mortality rate to earlier recognition, betterunderstanding of the pathophysiology of pulmonary hypertension, alongwith improvements in medical therapy and critical-care obstetrics. Recognition of the elevated maternal-fetal mortality rate has ledphysicians to recommend effective contraception and, in the event of
References (12)
- et al.
Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996
J Am Coll Cardiol
(1998) Pregnancy and cardiovascular disease
Med Clin North Am
(1977)- et al.
Pulmonary hypertension in pregnancy: treatment with pulmonary vasodilators
Obstet Gynecol
(1999) - et al.
Anesthesia for caesarean section in the presence of severe primary pulmonary hypertension
Br J Anaesth
(1998) - et al.
Primary pulmonary hypertension in pregnancy
Obstet Gynecol Surv
(1964) - et al.
Reduction in pulmonary vascular resistance with long term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
N Engl J Med
(1998)
Cited by (92)
Managing Specific Cardiac Conditions During Pregnancy, Labor, and Delivery
2022, Maternal Cardiac Care: A Guide to Managing Pregnant Women with Heart DiseasePregnancy and Pulmonary Arterial Hypertension: A Case Report
2021, Open Respiratory ArchivesPregnancy and pulmonary arterial hypertension: a case series and literature review
2021, American Journal of Obstetrics and Gynecology MFMCitation Excerpt :The available parenteral prostaglandins include epoprostenol, treprostinil, and iloprost, which can be delivered via IV or inhaled formulations. IV epoprostenol remains the only PAH-targeted therapy with a mortality benefit,35 and there is growing evidence supporting its use in pregnancy.36–38 In a report of 3 patients with PAH who were started on IV epoprostenol, all survived without postpartum complications.39
Pregnancy and pulmonary arterial hypertension
2019, Presse MedicaleChallenge of Pregnancy in Patients With Pre-Capillary Pulmonary Hypertension: Veno-Arterial Extracorporeal Membrane Oxygenation as an Innovative Support for Delivery
2017, Journal of Cardiothoracic and Vascular AnesthesiaCitation Excerpt :In the second patient, it was placed before the abdominal incision (preemptive). The authors’ limited experience suggests that successful pregnancy can be achieved in patients with advanced pre-capillary PH, after an individualized assessment and preparation of a plan by a multispecialist team with the help of modern circulatory assist devices.9,10 However, these results must be confirmed by a larger series before the general recommendation to avoid pregnancy in all patients with PH is reconsidered.
National Trends and In-Hospital Outcomes in Pregnant Women With Heart Disease in the United States
2017, American Journal of CardiologyCitation Excerpt :We demonstrate that women with PH are at highest risk for maternal in-hospital mortality during the hospitalization for delivery. Improvements in PH-associated maternal death have occurred in the last 3 decades18,23–26; however, the peripartum and particularly the postpartum periods pose increased risk. It has been postulated that the mode of delivery and anesthesia, rapid changes in blood volume, and autotransfusion immediately after birth from the uterus are possible factors.